ARCA Competitors

Delisted . USA . 
Stock . ARCA Biopharma
ARCA Biopharma competes with Aerovate Therapeutics, Adagene, Acrivon Therapeutics,, Rezolute, and AN2 Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing ARCA Biopharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of ARCA Biopharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of ARCA Biopharma competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.000.000.00
Details
Intrinsic
Valuation
LowRealHigh
0.000.000.00
Details

ARCA Biopharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between ARCA Biopharma and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of ARCA and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of ARCA Biopharma does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
FBRX
+ 0.95
ANTX
ACRV
+ 0.78
ADAG
ZIVO
+ 0.76
TPST
RZLT
+ 0.72
ADAG
ZIVO
+ 0.69
INDP
RZLT
+ 0.67
ACRV
  
High negative correlations   
ZIVO
- 0.8
FBRX
CMRA
- 0.79
AVTE
TPST
- 0.78
AVTE
ZIVO
- 0.73
ANTX
FBRX
- 0.64
INDP
ZIVO
- 0.63
AVTE

Risk-Adjusted Indicators

There is a big difference between ARCA Stock performing well and ARCA Biopharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze ARCA Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
AVTE  2.34  0.41  0.17  0.64  2.02 
(3.41)
 5.58 
(3.86)
 19.11 
ADAG  3.86  0.01  0.00 (0.04) 5.28 
(4.12)
 7.34 
(8.33)
 41.45 
ACRV  2.52 (0.16) 0.00 (0.08) 0.00 
 0.00 
 4.83 
(7.21)
 19.02 
RZLT  2.70 (0.12) 0.00 (0.07) 0.00 
 0.00 
 5.54 
(5.71)
 16.29 
ANTX  2.59  0.30  0.10  0.31  2.26 
(4.61)
 6.34 
(4.72)
 28.89 
INDP  4.67 (0.51) 0.00 (0.24) 0.00 
 0.00 
 12.60 
(9.40)
 49.41 
TPST  3.50 (0.96) 0.00 (0.63) 0.00 
 0.00 
 4.90 
(10.19)
 23.90 
CMRA  5.99 (0.04) 0.00 (0.01) 0.00 
 0.00 
 13.95 
(12.70)
 30.28 
FBRX  6.62  2.36  0.43  1.45  4.38 
(8.84)
 14.10 
(7.69)
 146.60 
ZIVO  3.01 (0.65) 0.00 (3.54) 0.00 
 0.00 
 5.31 
(6.67)
 36.36 
All Fundamental Data

ARCA Biopharma Competitive Analysis

The better you understand ARCA Biopharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, ARCA Biopharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across ARCA Biopharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
AVTE ADAG ACRV RZLT ANTX INDP TPST CMRA FBRX ZIVO
 1.19 
 2.56 
Aerovate
 8.29 
 1.88 
Adagene
 5.22 
 6.36 
Acrivon
 1.14 
 4.44 
Rezolute
 11.11 
 1.40 
AN2
 5.32 
 0.89 
Indaptus
 19.24 
 0.85 
Tempest
 1.54 
 0.66 
Comera
 1.71 
 19.01 
Forte
 0.55 
 1.81 
Zivo
Market Volatility
(90 Days Market Risk)
Somewhat reliable
Unstable
Somewhat reliable
Slightly risky
Moderately volatile
Dangerous
Moderately volatile
Very steady
Very risky
Very steady
Market Performance
(90 Days Performance)
OK
Very Weak
Very Weak
Very Weak
Modest
Very Weak
Very Weak
Very Weak
Good
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
About Average
Low
Low
Average
Low
Very High
Dangerous
Low
Dangerous
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Hold
Buy
Strong Buy
Strong Buy
Hold
Buy
Strong Buy
Not Available
Strong Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Buy
Strong Sell
Cautious Hold
Cautious Hold
Hold
Strong Sell
Strong Sell
Not Rated
Hold
Not Rated
Current Ratio
40.85
3.1
N/A
61.78
28.17
9.18
3.05
2.14
25.67
2.08
Net Asset
127.42 M
115.73 M
138.26 M
132.74 M
138.74 M
14.92 M
51.6 M
3.73 M
38.98 M
2.12 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
(81.31 M)
(14.95 M)
(59.85 M)
(68.42 M)
4.9 M
(16.38 M)
(28.78 M)
(13.33 M)
(32.48 M)
(8.73 M)
Current Valuation
(14.47 M)
15.43 M
28.57 M
148.18 M
(57.6 M)
3.78 M
27.92 M
9.96 M
108.69 M
2.02 M
Price To Book
0.92
1.6
1.08
2.24
0.43
1.84
2.82
N/A
13.35
17.86
Operating Margin
N/A
-45.35
N/A
N/A
N/A
N/A
N/A
-15.82
N/A
-133.25
Retained Earnings
(163.42 M)
(277.75 M)
(116.42 M)
(329.44 M)
(154.46 M)
(45.42 M)
(165.26 M)
(34.9 M)
(118.52 M)
(115.8 M)
Current Asset
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
28.93 K
Beta
1.0
0.58
N/A
1.19
-0.22
1.13
-2.78
1.16
1.46
0.27
Number Of Employees
51
174
58
59
41
7
17
12
11
8
Shares Outstanding
28.91 M
44.27 M
31.14 M
57.94 M
29.88 M
12.01 M
43.64 M
30.74 M
6.39 M
1.82 M
Cash Flow From Operations
(56.78 M)
(28.45 M)
(42.64 M)
(57.37 M)
(53.29 M)
(13.41 M)
(27.36 M)
(9.77 M)
(28.71 M)
(7.1 M)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.0424
Total Debt
675 K
22.31 M
4.64 M
2.23 M
14.04 M
175.05 K
20.66 M
775.05 K
3.67 M
445.18 K
Return On Equity
-0.82
-0.46
-0.38
-0.58
-0.69
-1.27
-2.89
-16.29
-1.71
-39.56
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-20.09
N/A
-87.31
Return On Asset
-0.49
-0.2
-0.24
-0.34
-0.43
-0.71
-0.54
-1.19
-0.81
-1.65
Number Of Shares Shorted
1.79 M
34.66 K
1.11 M
1.12 M
71.42 K
91.96 K
2.49 M
281.55 K
211.23 K
35.47 K
Book Value Per Share
2.79
1.28
5.38
2.27
4.19
1.44
1.21
-0.14
24.3
-0.63
Current Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
4.97 M
Total Asset
127.42 M
115.73 M
138.26 M
132.74 M
138.74 M
14.92 M
51.6 M
3.73 M
38.98 M
2.12 M
Debt To Equity
0.008
0.15
N/A
0.001
N/A
0.004
0.49
0.16
N/A
0.28
Short Ratio
0.98
0.33
15.38
3.16
0.82
0.54
0.39
0.84
0.09
6.65
Target Price
2.33
10.54
21.11
13.0
2.67
8.5
18.75
N/A
107.0
36.0
Shares Owned By Institutions
99.98
25.54
75.97
64.24
52.31
5.99
23.02
2.7
54.05
4.44
Market Capitalization
73.14 M
108.46 M
208.92 M
254.37 M
37.65 M
11.27 M
31.06 M
6.85 M
123.65 M
2 M
Price To Earning
0.64
N/A
N/A
N/A
3.96
N/A
0.23
N/A
N/A
-1.95
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
N/A
111.25
N/A
N/A
N/A
N/A
N/A
43.28
N/A
2639.17
Net Income
(75.52 M)
(18.95 M)
(60.39 M)
(68.46 M)
(64.73 M)
(15.42 M)
(29.49 M)
(18 M)
(31.48 M)
(8.75 M)
Earnings Per Share
-2.99
-0.72
-2.66
-1.27
-1.99
-1.7
-1.53
-0.22
-16.38
-5.33
Shares Owned By Insiders
0.02
10.65
22.38
13.74
21.63
26.67
0.24
51.33
10.94
25.23
Revenue
N/A
18.11 M
N/A
N/A
N/A
N/A
N/A
633.1 K
N/A
N/A
Working Capital
106.59 M
81.99 M
116.39 M
119.05 M
96.46 M
11.22 M
30.95 M
(2 M)
34.66 M
(126.04 K)
Cash And Equivalents
151.99 M
168.04 M
N/A
150.41 M
113.39 M
33.01 M
51.62 M
4.94 M
38.55 M
5.08 M
Cash Per Share
6.22
3.87
N/A
3.87
5.84
4.0
4.95
0.26
1.89
0.54
Gross Profit
N/A
10.18 M
N/A
N/A
N/A
N/A
N/A
422.71 K
N/A
20 K
Day Typical Price
2.56
1.94
6.63
4.4
1.36
0.9
0.8
0.65
18.86
1.82
Accumulation Distribution
6265.23
0.0918
0.11
8825.36
60917.66
2078.62
0.18
0.0896
0.0798
0.0688
Market Facilitation Index
N/A
0.19
0.82
0.0
N/A
0.0
0.15
0.06
1.56
0.13
Daily Balance Of Power
0.5
(0.89)
(0.43)
0.3333
0.8235
(0.83)
0.9107
0.1667
(0.21)
(0.08)
Period Momentum Indicator
0.03
(0.17)
(0.35)
0.05
0.14
(0.05)
0.1366
0.01
(0.33)
(0.01)
Rate Of Daily Change
1.01
0.92
0.95
1.01
1.11
0.95
1.19
1.02
0.98
0.99
Day Median Price
2.56
1.98
6.77
4.38
1.35
0.91
0.77
0.64
18.78
1.83
Price Action Indicator
0.015
(0.18)
(0.58)
0.09
0.12
(0.04)
0.14
0.025
0.065
(0.02)
Coefficient Of Variation
819.92
37252.72
(3,209)
(4,159)
1412.22
(1,608)
(513.88)
(155,105)
700.06
(722.69)
Mean Deviation
2.34
3.86
2.52
2.7
2.59
4.67
3.5
5.99
6.62
3.01
Jensen Alpha
0.4065
0.0084
(0.16)
(0.12)
0.3005
(0.51)
(0.96)
(0.04)
2.36
(0.65)
Total Risk Alpha
0.3222
(0.15)
(0.23)
(0.19)
0.1919
(0.67)
(1.06)
(0.23)
1.93
(0.78)
Sortino Ratio
0.1653
(0)
N/A
N/A
0.1019
N/A
N/A
N/A
0.4301
N/A
Downside Variance
5.83
30.55
N/A
N/A
8.77
N/A
N/A
N/A
30.5
N/A
Standard Deviation
3.54
5.68
3.74
3.45
4.72
7.31
4.72
7.65
16.85
4.62
Kurtosis
4.93
5.92
2.19
0.0373
13.17
5.35
2.46
0.1109
49.82
8.23
Potential Upside
5.58
7.34
4.83
5.54
6.34
12.6
4.9
13.95
14.1
5.31
Treynor Ratio
0.6356
(0.04)
(0.08)
(0.07)
0.306
(0.24)
(0.63)
(0.01)
1.45
(3.54)
Maximum Drawdown
19.11
41.45
19.02
16.29
28.89
49.41
23.9
30.28
146.6
36.36
Variance
12.5
32.27
13.96
11.88
22.25
53.51
22.29
58.52
284.02
21.38
Market Risk Adjusted Performance
0.6456
(0.03)
(0.07)
(0.06)
0.316
(0.23)
(0.62)
(0)
1.46
(3.53)
Risk Adjusted Performance
0.1044
0.0107
(0.02)
(0.01)
0.0644
(0.04)
(0.15)
0.0085
0.1227
(0.10)
Skewness
1.75
0.7682
(0.65)
0.0289
3.17
1.48
(1.14)
0.287
6.61
1.35
Semi Deviation
2.02
5.28
N/A
N/A
2.26
N/A
N/A
N/A
4.38
N/A
Information Ratio
0.1129
(0)
(0.04)
(0.03)
0.064
(0.07)
(0.20)
(0)
0.1409
(0.15)
Value At Risk
(3.86)
(8.33)
(7.21)
(5.71)
(4.72)
(9.40)
(10.19)
(12.70)
(7.69)
(6.67)
Expected Short fall
(3.41)
(4.12)
N/A
N/A
(4.61)
N/A
N/A
N/A
(8.84)
N/A
Downside Deviation
2.41
5.53
N/A
N/A
2.96
N/A
N/A
N/A
5.52
N/A
Semi Variance
4.08
27.84
N/A
N/A
5.11
N/A
N/A
N/A
19.18
N/A

ARCA Biopharma Competition Performance Charts

Five steps to successful analysis of ARCA Biopharma Competition

ARCA Biopharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by ARCA Biopharma in relation to its competition. ARCA Biopharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of ARCA Biopharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact ARCA Biopharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to ARCA Biopharma, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your ARCA Biopharma position

In addition to having ARCA Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Rentals Thematic Idea Now

Rentals
Rentals Theme
Companies providing rental and leasing services to public and business. The Rentals theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Rentals Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Other Consideration for investing in ARCA Stock

If you are still planning to invest in ARCA Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ARCA Biopharma's history and understand the potential risks before investing.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY